• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

Introduction to 2-Methyl-4-(piperidin-1-yl)aniline (CAS No. 73164-32-6)

2-Methyl-4-(piperidin-1-yl)aniline, identified by the Chemical Abstracts Service Number (CAS No.) 73164-32-6, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic amine derivative has garnered attention due to its structural complexity and potential biological activities, making it a subject of extensive study in drug discovery and development.

The molecular structure of 2-Methyl-4-(piperidin-1-yl)aniline consists of a benzene ring substituted with a methyl group at the 2-position and a piperidine moiety at the 4-position, linked through an amine group. This unique arrangement imparts distinct chemical and pharmacological properties, positioning it as a valuable scaffold for designing novel therapeutic agents. The presence of the piperidine ring enhances solubility and bioavailability, which are critical factors in drug formulation and delivery.

In recent years, there has been growing interest in exploring the pharmacological potential of 2-Methyl-4-(piperidin-1-yl)aniline. Research has indicated that this compound exhibits promising activities as an intermediate in synthesizing kinase inhibitors, particularly those targeting tyrosine kinases involved in cancer therapy. The piperidine nitrogen atom provides a hydrogen bond acceptor site, facilitating interactions with biological targets, while the aromatic system allows for further derivatization to enhance binding affinity.

One of the most compelling aspects of 2-Methyl-4-(piperidin-1-yl)aniline is its role in developing small-molecule inhibitors for neurological disorders. Studies have demonstrated its ability to modulate neurotransmitter receptors, such as serotonin and dopamine receptors, which are implicated in conditions like depression, anxiety, and neurodegenerative diseases. The structural motif of this compound aligns well with the binding pockets of these receptors, suggesting its utility as a lead compound for further optimization.

The synthesis of 2-Methyl-4-(piperidin-1-yl)aniline involves multi-step organic reactions that require precise control over reaction conditions to achieve high yields and purity. Common synthetic routes include nucleophilic substitution reactions followed by functional group transformations. Advanced techniques such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions have been employed to streamline the synthesis process and improve scalability.

From a computational chemistry perspective, 2-Methyl-4-(piperidin-1-yl)aniline has been extensively studied using molecular modeling techniques to predict its interactions with biological targets. These studies have provided insights into the binding modes of the compound, helping researchers design more effective derivatives with enhanced pharmacokinetic properties. The integration of computational methods with experimental validation has accelerated the discovery process for novel drug candidates.

The pharmaceutical industry has shown particular interest in leveraging 2-Methyl-4-(piperidin-1-yl)aniline as a building block for drug development. Its versatility allows for modifications at multiple positions on the molecule, enabling the creation of libraries of compounds with tailored biological activities. High-throughput screening (HTS) campaigns have been conducted using derivatives of this compound to identify hits with desirable therapeutic profiles.

In conclusion, 2-Methyl-4-(piperidin-1-yl)aniline (CAS No. 73164-32-6) represents a fascinating compound with significant potential in pharmaceutical research. Its unique structural features make it an attractive candidate for developing drugs targeting various diseases, including cancer and neurological disorders. As research continues to uncover new applications for this molecule, its importance in medicinal chemistry is likely to grow further.

• 143525-69-3(2-methyl-4-(pyrrolidin-1-yl)aniline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)